The myeloproliferative disorders
PJ Campbell, AR Green - New England Journal of Medicine, 2006 - Mass Medical Soc
PJ Campbell, AR Green
New England Journal of Medicine, 2006•Mass Medical SocThe discovery of an identical mutation (V617F) of the JAK2 gene in patients with
polycythemia vera, essential thrombocythemia, and myelofibrosis—the principal
Philadelphia chromosome–negative myeloproliferative disorders—has greatly advanced
our understanding of these conditions. This article reviews the legacy of this discovery and
how it has changed our view of the origins, interrelations, and management of the
myeloproliferative disorders.
polycythemia vera, essential thrombocythemia, and myelofibrosis—the principal
Philadelphia chromosome–negative myeloproliferative disorders—has greatly advanced
our understanding of these conditions. This article reviews the legacy of this discovery and
how it has changed our view of the origins, interrelations, and management of the
myeloproliferative disorders.
The discovery of an identical mutation (V617F) of the JAK2 gene in patients with polycythemia vera, essential thrombocythemia, and myelofibrosis — the principal Philadelphia chromosome–negative myeloproliferative disorders — has greatly advanced our understanding of these conditions. This article reviews the legacy of this discovery and how it has changed our view of the origins, interrelations, and management of the myeloproliferative disorders.
The New England Journal Of Medicine